MLSS MILESTONE SCIENTIFIC INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 855683 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.9%
TTM net income YoY46.6%
TTM EPS YoY55.6%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin70.9%
Operating margin-40.0%
Net margin-38.3%
FCF margin-16.0%
EBITDA margin-39.2%
Returns
ROE-114.7%
ROA-46.1%
ROIC (approx.)-165.6%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets47.3%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-27.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.97M | $8.63M | $9.83M | $8.81M | $10.30M |
| Cost of revenue | $2.57M | $2.20M | $3.03M | $3.91M | $3.99M |
| Gross profit | $6.41M | $6.43M | $6.79M | $4.90M | $6.31M |
| R&D expense | $449,469 | $858,767 | $701,378 | $1.15M | $878,210 |
| SG&A expense | $11.58M | $12.30M | $13.14M | $12.51M | $12.74M |
| Operating income | -$5.70M | -$6.76M | -$7.11M | -$8.83M | -$7.38M |
| Pretax income | -$5.72M | -$4.71M | -$6.98M | -$8.77M | -$7.12M |
| Income tax | — | — | $0 | $0 | $333 |
| Net income | -$5.72M | -$4.71M | -$6.93M | -$8.71M | -$6.82M |
| EBITDA | -$5.62M | -$6.72M | -$7.04M | -$8.76M | -$7.30M |
| EPS (basic) | -0.07 | -0.06 | -0.10 | -0.12 | -0.10 |
| EPS (diluted) | -0.07 | -0.06 | — | — | -0.10 |
| Weighted avg. shares (diluted) | 82.06M | 79.79M | — | — | 68.83M |
| Banking | |||||
| Net interest income | — | $60,265 | $125,527 | $54,607 | -$16,360 |
| Balance sheet | |||||
| Cash & equivalents | $1.11M | $3.26M | $2.98M | $8.72M | $14.76M |
| Short-term investments | — | $0 | $2.98M | $0 | $14.80M |
| Receivables | — | $475,376 | $312,664 | $693,717 | $943,272 |
| Inventory | $3.78M | $3.71M | $2.64M | $1.79M | $1.54M |
| Current assets | $7.48M | $9.29M | $10.79M | $12.97M | $18.93M |
| PP&E, net | $19,193 | $12,921 | $10,024 | $18,146 | $23,713 |
| Intangibles | $79,063 | $148,404 | $178,636 | $227,956 | $277,619 |
| Total assets | $7.81M | $9.80M | $11.37M | $13.70M | $19.81M |
| Current liabilities | $3.94M | $3.74M | $3.08M | $3.30M | $3.10M |
| Total liabilities | $4.80M | $3.96M | $3.36M | $3.70M | $3.59M |
| Shareholders' equity | $3.01M | $5.83M | $8.01M | $10.23M | $16.37M |
| Shares outstanding | 80.45M | 78.01M | 75.85M | 69.27M | 68.12M |
| Cash flow statement | |||||
| Operating cash flow | -$2.92M | -$2.92M | -$5.33M | -$6.03M | -$4.03M |
| Capital expenditure | $15,124 | $10,124 | — | $8,527 | $15,189 |
| Free cash flow | -$2.93M | -$2.93M | — | -$6.04M | -$4.05M |
| Investing cash flow | -$15,124 | $2.97M | -$2.97M | -$8,527 | -$15,189 |
| Financing cash flow | $786,335 | $233,771 | $2.56M | -$8,544 | $4.59M |
| Depreciation & amortization | $78,195 | $37,448 | $61,912 | $63,755 | $73,836 |
| Stock-based compensation | $952,716 | $1.35M | $1.47M | $1.50M | $790,915 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.